1-氨甲基-5-甲氧基茚滿
外觀
![]() | |
臨床資料 | |
---|---|
給藥途徑 | 口服 |
ATC碼 |
|
法律規範狀態 | |
法律規範 |
|
識別資訊 | |
| |
CAS號 | 1415750-28-5 ![]() |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C11H15NO |
摩爾質量 | 177.25 g·mol−1 |
3D模型(JSmol) | |
| |
|
1-氨甲基-5-甲氧基茚滿(英語:1-Aminomethyl-5-methoxyindane,簡稱AMMI),是一種由普渡大學的大衛·厄爾·尼科爾斯領導的團隊開發的藥物,它作為選擇性血清素釋放劑並與和DiFMDA具有相似親和力的血清素轉運蛋白結合。[1][2]
參見
[編輯]參考資料
[編輯]- ^ Roman DL, Saldaña SN, Nichols DE, Carroll FI, Barker EL. Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters. The Journal of Pharmacology and Experimental Therapeutics. February 2004, 308 (2): 679–87. PMID 14593087. S2CID 6439942. doi:10.1124/jpet.103.057836.
- ^ Walline CC, Nichols DE, Carroll FI, Barker EL. Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition. The Journal of Pharmacology and Experimental Therapeutics. June 2008, 325 (3): 791–800. PMC 2637348
. PMID 18354055. doi:10.1124/jpet.108.136200.